Clarity Pharmaceuticals Ltd. is a clinical stage radiopharmaceutical company. The company is headquartered in Eveleigh, New South Wales. The company went IPO on 2021-08-25. The firm is focused on developing theranostic (therapy and imaging) products, based on its platform SAR Technology. The company is progressing seven clinical trials with its three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2), including neuroblastoma and neuroendocrine tumors (NETs). SAR-bisPSMA is developed for diagnosing, staging, and treating cancers that express Prostate Specific Membrane Antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer. The company has a diverse range of products in clinical trials, which address both large indications as well as rare and orphan indications of cancer.
Follow-Up Questions
What is the price performance of CLRPF stock?
The current price of CLRPF is $2.42, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Clarity Pharmaceuticals Ltd?
Clarity Pharmaceuticals Ltd belongs to Pharmaceuticals industry and the sector is Health Care
What is Clarity Pharmaceuticals Ltd market cap?
Clarity Pharmaceuticals Ltd's current market cap is $900.0M
Is Clarity Pharmaceuticals Ltd a buy, sell, or hold?
According to wall street analysts, 8 analysts have made analyst ratings for Clarity Pharmaceuticals Ltd, including 2 strong buy, 6 buy, 1 hold, 0 sell, and 2 strong sell
